Autolus Therapeutics AUTL
NASDAQ AUTL
$2.24 -0.05 (-2.18%)
As of: Sep 4, 2026 · 3:12 PM EDT

Autolus Therapeutics (AUTL) Non Operating Interest Expenses (2021 - 2026)

Analysis

Autolus Therapeutics (AUTL) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Autolus Therapeutics 596.20 Mn 394.57 Mn 25.22 Mn -2.67 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.67 Mn
Dec 31, 2025 22.84 Mn
Sep 30, 2025 10.52 Mn
Jun 30, 2025 -6.83 Mn
Mar 31, 2025 10.14 Mn
Dec 31, 2024 -30.84 Mn
Sep 30, 2024 10.69 Mn
Jun 30, 2024 10.17 Mn
Mar 31, 2024 19.27 Mn
Dec 31, 2023 30.13 Mn
Sep 30, 2023 5.01 Mn
Jun 30, 2023 5.02 Mn
Mar 31, 2023 4.91 Mn
Dec 31, 2022 3.46 Mn
Sep 30, 2022 1.85 Mn
Jun 30, 2022 1.81 Mn
Mar 31, 2022 1.79 Mn
Dec 31, 2021 1.11 Mn